T cell therapy platform mediated by antigen-specific TCR complex can improve the sensitivity of T cell antigen recognition, enhance cell persistence and potentiate clinical efficacy and durability.

Innovative AI-driven high-throughput single-cell TCR screening platform by transcriptomic and functional analyses significantly reduces time and cost in drug development.

Advanced armoring technology aims to solve the safety and persistence of traditional CAR-T cell therapy by targeting the tumor microenvironment and heterogeneity of solid tumors.

Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. The Chongqing site was launched in 2017, and the facilities in LA and Guangzhou were launched in 2019 and 2020, respectively.